Abstract
Cerebral vasospasm remains a formidable obstacle to the recovery of patients surviving aneurysmal subarachnoid hemorrhage. Its mechanisms appear to be complex and knowledge of them is incomplete, resulting in relatively indirect and often ineffective treatments. Particularly acknowledged is the occurrence of vasospasm in smaller-caliber resistance vessels, capable of causing significant neurological dysfunction yet not easily detectable by transcranial Doppler examination or cerebral angiography. Therapeutic options for this type of vasospasm are very limited. Molecular-level investigations in recent years have shed some light upon possible mechanisms of vasospasm that may be amenable to therapeutic intervention by manipulation. The introduction of the nitric oxide molecule to the adventitial microenvironment through intrathecal administration is one such manipulation based on hypothesis-driven research; it has recently been introduced to the clinical setting by the author and is the subject of this report.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
